Table 1.
Baseline characteristics
| Characteristics | Total (N = 34) | TQB2450 1200 mg+anlotinib 10 mg (N = 3) | TQB2450 1200 mg+anlotinib 12 mg (N = 31) |
|---|---|---|---|
| Age (years), median (range) | 50.0 (32.0, 70.0) | 48.0 (48.0, 64.0) | 50.0 (32.0, 70.0) |
| <65, n (%) | 31 (91.2) | 3 (100) | 28 (90.3) |
| ≥65, n (%) | 3 (8.8) | 0 | 3 (9.7) |
| ECOG performance status, n (%) | |||
| 0 | 30 (88.2) | 3 (100) | 27 (87.1) |
| 1 | 4 (11.8) | 0 | 4 (12.9) |
| Metastatic site, n (%) | |||
| Non-visceral | 30 (88.2) | 3 (100) | 27 (87.1) |
| Visceral | 20 (58.8) | 0 | 20 (64.5) |
| Number of metastatic sites, n (%) | |||
| 1 | 6 (17.7) | 2 (66.7) | 4 (12.9) |
| 2 | 13 (38.2) | 1 (33.3) | 12 (38.7) |
| ≥3 | 15 (44.12) | 0 | 15 (48.4) |
| Chest wall metastasis, n (%) | 10 (29.4) | 2 (66.7) | 8 (25.8) |
| Liver metastasis, n (%) | 8 (23.5) | 0 | 8 (25.8) |
| Bone metastasis, n (%) | 10 (29.4) | 0 | 10 (32.3) |
| Lung metastasis, n (%) | 12 (35.3) | 0 | 12 (38.7) |
| Lymph nodes metastasis, n (%) | 24 (70.6) | 2 (66.7) | 22 (71.0) |
| Pleural effusion metastasis, n (%) | 3 (8.8) | 0 | 3 (9.7) |
| Pericardium metastasis, n (%) | 0 | 0 | 0 |
| Previous chemotherapy, n (%) | |||
| Anthracyclines | 32 (94.1) | 3 (100) | 29 (93.5) |
| Taxanes | 31 (91.2) | 3 (100) | 28 (90.3) |
| Platinum | 16 (47.1) | 2 (66.7) | 14 (45.2) |
| Previous neoadjuvant therapy, n (%) | 9 (26.5) | 1 (33.3) | 8 (25.8) |
| Previous adjuvant therapy, n (%) | 25 (73.5) | 3 (100) | 22 (71.0) |
| Number of previous therapy lines | |||
| Median (range) | 1 (0, 4) | 1 (1, 1) | 1 (0, 4) |
| 0, n (%) | 1 (2.9) | 0 | 1 (3.2) |
| 1, n (%) | 26 (76.5) | 3 (100) | 23 (74.2) |
| 2, n (%) | 4 (11.8) | 0 | 4 (12.9) |
| >2, n (%) | 3 (8.8) | 0 | 3 (9.7) |
| PD-L1 expression, n (%) | |||
| Negative | 13 (38.2) | 1 (33.3) | 12 (38.7) |
| Positive | 6 (17.6) | 1 (33.3) | 5 (16.1) |
| Unknown | 15 (44.1) | 1 (33.3) | 14 (45.2) |
ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death-ligand 1. Demographics were summarized with descriptive statistics.